Article
作者: González, Liliana A. ; Vázquez, Yaneisi ; González-Aramundiz, José V. ; Soto-Rifo, Ricardo ; Hoppe-Elsholz, Guillermo ; Ríos, Mariana ; Rivera-Pérez, Daniela ; Berríos-Rojas, Roslye V. ; Fasce, Rodrigo ; Schultz, Bárbara M. ; Weiskopf, Daniela ; Ramírez, Eugenio ; Urzua, Marcela ; Duarte, Luisa F. ; Gálvez, Nicolás M. S. ; Acevedo, Mónica L. ; Mora, Judith ; Melo-González, Felipe ; Vallejos, Omar P. ; Soto, Jorge A. ; Iturriaga, Carolina ; Navarrete, María S. ; Andrade-Parra, Catalina A. ; Abarca, Katia ; Grifoni, Alba ; Meng, Weining ; Fernández, Jorge ; Piña-Iturbe, Alejandro ; Valiente-Echeverría, Fernando ; Sette, Alessandro ; Kalergis, Alexis M. ; Bueno, Susan M. ; González, Pablo A. ; Zeng, Gang ; Pacheco, Gaspar A. ; Moreno-Tapia, Daniela ; Rojas, Álvaro ; Gaete-Argel, Aracelly
CoronaVac is an inactivated vaccine against SARS-CoV-2 that has been approved by WHO for emergency use. Phase III clinical trials are in progress in several countries, including China, Brazil, Turkey, and Chile, and have shown safety and immunogenicity after two doses of the vaccine.